In this Issue:
The risk of cardiotoxicity with trastuzumab
Venepuncture and lymphoedema precautions
. . . can we abandon old practices?
Contralateral breast cancer risk in BRCA1/2 mutation carriers
Selecting adjuvant endocrine therapy for premenopausal HR+/HER2– disease
MDS/AML risk with specific breast cancer treatments
LCIS and the risk of breast cancer
Adjuvant lapatinib + trastuzumab for early HER2+ disease
Aerobic exercise lowers oestrogen levels in premenopausal women
The patient’s perspective on chemotherapy-related adverse effects
Please login below to download this issue (PDF)